Status:

COMPLETED

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

Lead Sponsor:

AOP Orphan Pharmaceuticals AG

Conditions:

Cystic Fibrosis

Eligibility:

All Genders

12+ years

Phase:

PHASE2

Brief Summary

This is a dose-finding study for the investigational product Lancovutide (Moli1901) in the exploratory phase IIb to establish minimum effective dose, optimal dose, and maximum safe dose. Additionally,...

Detailed Description

Study Moli1901-010B is a multi center, parallel group, placebo controlled, double-blind efficacy and safety evaluation of three different dosage schedules of aerosolized Moli1901 in adolescents (12 ye...

Eligibility Criteria

Inclusion

  • Body mass index
  • Confirmed diagnosis of cystic fibrosis
  • FEV1 between 50% and 85% of predicted
  • Oxygen saturation level measured by pulse oximetry (SpO2) \>90 % on room air

Exclusion

  • Bronchial hyperresponsiveness
  • Unstable lung function
  • Pulmonary disease such as pneumonia, tuberculosis, or lung cancer
  • Acute upper respiratory tract infection within the last 2 weeks
  • Acute lower respiratory tract infection (requiring antibiotics or hospitalization) within the last 4 weeks
  • Pulmonary exacerbation within the last 4 weeks
  • Changes from routine maintenance therapy within the last 4 weeks
  • Scheduled changes to inhaled antibiotics regimen during the course of the study
  • Receive or are planned to receive any treatment via "on-off" regimen (e.g. Tobramycin - TOBI®); last dose of any "on-off" treatment within the last 6 weeks
  • Any clinically significant liver, renal, cardiac, neurological, or hematological disease
  • ABPA or colonization with Burkholderia cepacia
  • Poorly controlled diabetes mellitus

Key Trial Info

Start Date :

October 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2009

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT00671736

Start Date

October 1 2007

End Date

July 1 2009

Last Update

August 27 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University

Graz, Austria, 8086

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis | DecenTrialz